Cerevel Therapeutics Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. was a United States-based biopharmaceutical company formerly listed on the NASDAQ market. It was focused on neuroscience, with a particular emphasis on central nervous system disorders such as schizophrenia, Parkinson’s disease, and other psychiatric or neurological conditions. The company was founded in 2018, emerging from assets originally associated with Pfizer, and it established its headquarters in Cambridge, Massachusetts, a leading U.S. biotech hub. Cerevel’s business model was that of a development-stage biotechnology company: it was centered on research, preclinical work, and clinical trials rather than on a mature commercial product base. Its pipeline was built around a handful of high-profile neuroscience candidates. The most closely watched programs included emraclidine, an oral next-generation antipsychotic being studied in schizophrenia, and tavapadon, a once-daily candidate for Parkinson’s disease. The company also advanced additional neuroscience assets aimed at improving treatment options in areas where current standards of care can be limited by efficacy or tolerability challenges. From a competitive standpoint, Cerevel operated as a focused specialty biotech in a highly demanding segment of the pharmaceutical industry. Its strategic value came from the perceived quality of its pipeline and the potential for differentiated clinical data, rather than from current revenue generation. In that sense, Cerevel represented a classic high-risk/high-reward neuroscience platform: substantial research and development spending, limited near-term commercial visibility, and significant dependence on clinical milestones. The company competed indirectly with large multinational pharmaceutical groups, as well as with smaller biotech peers pursuing new mechanisms in psychiatry and neurology. A major recent development reshaped the investment case. AbbVie announced in December 2023 that it would acquire Cerevel, and the transaction was completed on August 1, 2024. As a result, Cerevel no longer trades as an independent public company; it has been integrated into AbbVie. For investors in France, Belgium, and Switzerland, Cerevel is therefore best viewed today as a historical NASDAQ-listed neuroscience biotech rather than an ongoing standalone equity story. Its legacy remains relevant mainly through the assets AbbVie inherited, especially emraclidine and tavapadon, which were central to the rationale for the acquisition.